

Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis.

M Shinohara, ... , J Onorato, M Brownlee

J Clin Invest. 1998;101(5):1142-1147. <https://doi.org/10.1172/JCI119885>.

Research Article

Methylglyoxal (MG), a dicarbonyl compound produced by the fragmentation of triose phosphates, forms advanced glycation endproducts (AGEs) in vitro. Glyoxalase-I catalyzes the conversion of MG to S-D-lactoylglutathione, which in turn is converted to D-lactate by glyoxalase-II. To evaluate directly the effect of glyoxalase-I activity on intracellular AGE formation, GM7373 endothelial cells that stably express human glyoxalase-I were generated. Glyoxalase-I activity in these cells was increased 28-fold compared to neo-transfected control cells (21.80±0.1 vs. 0.76±0.02 micromol/min/mg protein, n = 3, P < 0.001). In neo-transfected cells, 30 mM glucose incubation increased MG and D-lactate concentration approximately twofold above 5 mM (35.5±5.8 vs. 19.6±1.6, P < 0.02, n = 3, and 21.0±1.3 vs. 10.0±1.2 pmol/10(6) cells, n = 3, P < 0.001, respectively). In contrast, in glyoxalase-I-transfected cells, 30 mM glucose incubation did not increase MG concentration at all, while increasing the enzymatic product D-lactate by > 10-fold (18.9±3.2 vs. 18.4±5.8, n = 3, P = NS, and 107.1±9.0 vs. 9.4±0 pmol/10(6) cells, n = 3, P < 0.001, respectively). After exposure to 30 mM glucose, intracellular AGE formation in neo cells was increased 13.6-fold (2.58±0.15 vs. 0.19±0.03 total absorbance units, n = 3, P < 0.001). Concomitant with increased intracellular AGEs, macromolecular endocytosis by these cells was increased 2.2-fold. Overexpression of glyoxalase-I completely prevented both hyperglycemia-induced AGE formation [...]

Find the latest version:

<https://jci.me/119885/pdf>



Overexpression of Glyoxalase-I in Bovine Endothelial Cells Inhibits Intracellular Advanced Glycation Endproduct Formation and Prevents Hyperglycemia-induced Increases in Macromolecular Endocytosis

Moritsugu Shinohara,* P.J. Thornalley,† Ida Giardino,* Paul Beisswenger,§ Suzanne R. Thorpe,|| Joelle Onorato,|| and Michael Brownlee*

*Department of Medicine and the Diabetes Research Center, Albert Einstein College of Medicine, New York 10461; †Department of Biological and Chemical Sciences, University of Essex, Central Campus, Wivenhoe Park, Colchester, Essex CO35Q, United Kingdom;

§Department of Medicine, Endocrine-Metabolism Division, Dartmouth Medical School, Hanover, New Hampshire 03755; and

||Department of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina 29208

Abstract

Methylglyoxal (MG), a dicarbonyl compound produced by the fragmentation of triose phosphates, forms advanced glycation endproducts (AGEs) in vitro. Glyoxalase-I catalyzes the conversion of MG to *S*-D-lactoylglutathione, which in turn is converted to D-lactate by glyoxalase-II. To evaluate directly the effect of glyoxalase-I activity on intracellular AGE formation, GM7373 endothelial cells that stably express human glyoxalase-I were generated. Glyoxalase-I activity in these cells was increased 28-fold compared to *neo*-transfected control cells (21.80 ± 0.1 vs. 0.76 ± 0.02 $\mu\text{mol}/\text{min}/\text{mg}$ protein, $n = 3$, $P < 0.001$). In *neo*-transfected cells, 30 mM glucose incubation increased MG and D-lactate concentration approximately twofold above 5 mM (35.5 ± 5.8 vs. 19.6 ± 1.6 , $P < 0.02$, $n = 3$, and 21.0 ± 1.3 vs. 10.0 ± 1.2 pmol/ 10^6 cells, $n = 3$, $P < 0.001$, respectively). In contrast, in glyoxalase-I-transfected cells, 30 mM glucose incubation did not increase MG concentration at all, while increasing the enzymatic product D-lactate by > 10-fold (18.9 ± 3.2 vs. 18.4 ± 5.8 , $n = 3$, $P = \text{NS}$, and 107.1 ± 9.0 vs. 9.4 ± 0 pmol/ 10^6 cells, $n = 3$, $P < 0.001$, respectively). After exposure to 30 mM glucose, intracellular AGE formation in *neo* cells was increased 13.6-fold (2.58 ± 0.15 vs. 0.19 ± 0.03 total absorbance units, $n = 3$, $P < 0.001$). Concomitant with increased intracellular AGEs, macromolecular endocytosis by these cells was increased 2.2-fold. Overexpression of glyoxalase-I completely prevented both hyperglycemia-induced AGE formation and increased macromolecular endocytosis. (*J. Clin. Invest.* 1998. 101:1142–1147.) Key words: advanced glycation endproducts • methylglyoxal • glyoxalase-I • cell lines • endocytosis

Introduction

Chronic hyperglycemia is the primary etiologic factor in the pathogenesis of diabetic microvascular disease (1). A relation-

ship between hyperglycemia and diabetic macrovascular disease is also supported by recent literature (2, 3). The mechanisms by which hyperglycemia may damage vascular cells include increased polyol pathway flux associated with myo-inositol depletion and decreased Na/K ATPase activity (4), alterations in redox state (5), synthesis of diacylglycerol with activation of the protein kinase C BII isoform (6), production of reactive oxygen species (7), and nonenzymatic modification of proteins by glucose-derived advanced glycation endproducts (AGEs)¹ (8, 9). Recently, we have shown that AGEs accumulate much more rapidly inside endothelial cells than they do on extracellular proteins, increasing 13.8-fold after only 1 wk of incubation in high glucose-containing media (10). This observation suggests that inside cells, highly reactive AGE precursors are generated at a faster rate than outside cells, perhaps from glycolytic intermediates that are uniquely present in cells. In model systems, AGEs have been shown to arise from both metal-catalyzed autoxidation of glucose with the dicarbonyl glyoxal and arabinose as intermediates (11), and from decomposition of the Amadori product to the reactive dicarbonyl 3-deoxyglucosone (3-DG) (12). The dicarbonyl methylglyoxal (MG), produced by nonenzymatic fragmentation of triose phosphates, also forms AGEs in vitro, and has been postulated to be a major source of intracellular and plasma AGEs (13) (Fig. 1).

MG is efficiently metabolized by the glyoxalase system, where MG is first converted by glyoxalase-I to *S*-D-lactoylglutathione in the presence of reduced glutathione as an essential cofactor, and then converted to D-lactate by glyoxalase-II. MG can also be converted into the AGE precursor acetol by the enzyme aldose reductase, although the k_{cat}/K_m is > 100-fold less than for glyoxalase-I (14, 15). In situ activity of glyoxalase-I in human tissue calculated from measured enzyme protein concentrations and kinetic constants is 10–40 times higher than that of aldose reductase for all tissue except for kidney medulla (14).

In this study, we have investigated the role of MG in intracellular AGE formation by using a glyoxalase-I inhibitor, *S*-[*N*-hydroxy-*N*-(4-chlorophenyl) carbamoyl] glutathione diethyl ester (HCCG) and by generating GM7373 endothelial cells that stably express human glyoxalase-I. The effect of glyoxalase-I overexpression on glyoxal, 3-DG, MG, D-lactate, and acetol was determined, as well as the effect on intracellular AGE content. Since inhibition of intracellular AGEs by aminoguanidine

Address correspondence to Dr. Michael Brownlee, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461. Phone: 718-430-3636; FAX: 718-430-8570; E-mail: brownlee@aecom.yu.edu

Received for publication 22 November 1996 and accepted in revised form 1 January 1998.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/98/03/1142/06 \$2.00

Volume 101, Number 5, March 1998, 1142–1147

<http://www.jci.org>

1. Abbreviations used in this paper: 3-DG, 3-deoxyglucosone; AGE, advanced glycation endproduct; bFGF, basic fibroblast growth factor; CEL, carboxyethyllysine; CML, carboxymethyllysine; HCCG, *S*-[*N*-hydroxy-*N*-(4-chlorophenyl) carbamoyl] glutathione diethyl ester; MG, methylglyoxal; TDQ, 2-(2,3,4-trihydroxybutyl)-6,7-dimethoxyquinoxaline.




Figure 1. Schematic representation of potential pathway leading to AGE formation. AGEs arise from autoxidation of glucose to glyoxal, decomposition of the Amadori product to 3-DG, and the glyceraldehyde fragmentation product MG, which all react with amino groups of proteins. MG is metabolized to the unreactive D-lactate by the glyoxalase system (see Introduction for details).

has been shown to reduce hyperglycemia-induced increases in macromolecular endocytosis, the effect of glyoxalase-I overexpression on this phenomenon was also investigated (16).

Methods

Cell culture conditions. Transformed fetal bovine aortic endothelial cells, GM7373 cells (17), were obtained from the National Institute of General Medical Sciences Human Genetic Mutant Cell Repository (Camden, NJ). The cells were maintained in MEM containing 10% fetal bovine serum, essential and nonessential amino acids, and antibiotics, but no insulin. Confluent cells used for experiments were incubated in MEM containing 0.4% fetal bovine serum (growth arrest conditions) to mimic the state of endothelial cells in vivo, with either 5 or 30 mM glucose for 7 d. Culture medium was changed twice daily, and glucose concentration was measured before each change of medium using a glucose analyzer (Beckman, Brea, CA). Cell viability was checked using methylene blue exclusion. There was no change in viability under any of the experimental conditions over the 7-d period. The media and all supplements were purchased from Gibco (Grand Island, NY). GM7373 cells were also incubated with 40 μ M of the glyoxalase-I inhibitor, HCCG (18) (gift of Dr. D.J. Creighton, Department of Chemistry and Biochemistry, University of Maryland, Baltimore, MD) for 4 d with media changed twice a day. A preliminary dose-response curve using 10, 20, 40, 80, and 100 μ M of inhibitor showed that cell viability began to decrease at a concentration of 80 μ M. All experiments were performed three times with triplicate replicates.

Cell cytosol preparation. Cytosolic fractions of confluent cells

were prepared as described previously (19). Briefly, the cells were trypsinized, lysed in PBS containing proteinase inhibitors by three cycles of freezing and thawing and sonication at 4°C for 1 min, and then centrifuged at 12,000 g for 20 min. The supernatant was used as the cytosolic fraction.

Glyoxalase-I assay. The glyoxalase-I assay was performed according to a spectrophotometric method monitoring the increase in absorbance at 240 nm due to the formation of S-D-lactoylglutathione for 2 min at 25°C (20). The standard assay mixture contained 7.9 mM MG, 1 mM glutathione, 14.6 mM magnesium sulfate, and 182 mM imidazole HCl, pH 7.0. Before initiating the reaction by adding the cytosolic fraction (10–30 μ g) to the assay mixture, the mixture was allowed to stand for at least 2 min to ensure the equilibration of hemithioacetal formation. One unit of activity is defined as the formation of 1 mmol of S-D-lactoylglutathione/min/mg cell protein. Protein concentration was determined by Coomassie plus protein assay reagent (Pierce Chemical Co., Rockford, IL).

Measurement of total intracellular AGE protein. Equal amounts of cytosolic protein from cells incubated under different conditions were dot blotted onto nitrocellulose membranes (Schleicher and Schuell, Inc., Keene, NH). AGEs were detected by using the monoclonal anti-AGE antibody 6D12, which recognizes carboxymethyllysine (CML) like structures, as well as carboxyethyllysine (CEL) and several unidentified AGE epitopes (21). The immunocomplexes were visualized using an enhanced chemiluminescence kit (Amersham International, Amersham, UK) and evaluated by scanning densitometry using the Ultrascan XL (LKB, Uppsala, Sweden). The assay was standardized as described previously (22). To confirm that this antibody recognized MG modified proteins, human serum albumin minimally modified by MG was assayed by immunoblotting. The minimally modified protein was made as described previously: 0.1 mM HSA and purified MG were incubated in 0.1 M sodium phosphate buffer, pH 7.4, at 37°C for 24 h, then dialyzed extensively against Dulbecco's modified PBS (23). Immunoblots with mAb 6D12 showed a linear dependence on both MG-modified protein concentration and on MG concentration when incubated with an invariant amount of protein (data not shown). To determine whether the mAb 6D12 was in fact detecting changes in intracellular CML, MG-derived CEL, or an unidentified MG-derived epitope, CML and CEL were quantitated in 1.5 mg of cytosol protein by gas chromatography/mass spectrometry as described previously (24, 25) in both *neo*- and glyoxalase-I-transfected cells.

Measurement of macromolecular endocytosis. The endocytosis assay was performed as described previously (16). Briefly, confluent *neo* and glyoxalase-I-expressing cells were exposed to either 5 or 30 mM glucose as described. After 10 d the cells were incubated with 100 μ g/ml horseradish peroxidase type II (Sigma Chemical Co., St. Louis, MO) for 30 min at 37°C. The cells were washed thoroughly with PBS, trypsinized, and counted. Equal numbers of cells were lysed in 50-mM citrate phosphate buffer (pH 5) by sonication for 30 s. 50 μ l of each cell lysis was transferred to 96-well ELISA plates and incubated with 50 μ l of 4 mM O-phenylenediamine (Sigma Chemical Co.) and 0.004% H₂O₂ in citrate phosphate buffer for 1 h at room temperature. The reaction was stopped with 0.2 M H₂SO₄ and the OD was read at 495 nm.

Generation of GM7373 cells that stably express human glyoxalase-I. The human glyoxalase-I cDNA (26) was provided by Dr. Kenneth D. Tew (Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA). A 0.6-kb fragment of the human glyoxalase-I cDNA in PUC13 was cut out by EcoRI sites and ligated into HSVPrPuc (27–29) digested with the same enzyme. The introduction of the pHSV-Puc glyoxalase-I into the cells was performed by cotransfection with pSV7-*neo* (30) using a liposome method (31). Briefly, the cells (2.5×10^6) were incubated with both 25 μ g of the pHSV-Puc glyoxalase-I and pSV7-*neo* in the presence of 40 μ l of lipofectin (GIBCO BRL, Gaithersburg, MD) in 2 ml of serum-free medium for 5 h. The glyoxalase-I is under the transcriptional control of the HSV immediate early 4/5 promoter in this vector. The transfected cells were selected against G-418 (32). The expression of the gene was demonstrated by

both Western blotting using an antibody against human glyoxalase-I (gift of Dr. Kenneth D. Tew) and by measuring the enzyme activity. Immunocomplexes on the blotting membrane were visualized using an enhanced chemiluminescence kit (Amersham International).

Measurement of α -oxoaldehydes in cells. Glyoxal (40% aqueous solution) was purchased from Sigma Chemical Co. MG and 3-DG were prepared, purified, and characterized as described previously (33, 34). Stock solutions of MG and glyoxal were calibrated by end point enzymatic assay with glyoxalase-I (35) using molar changes of the extinction coefficient for the formation of the corresponding S-2-hydroxyacylglutathione deduced from reference 36. The concentration of glyoxal, 3-DG, and MG were determined in endothelial cell cytosol by derivatization of the α -oxoaldehydes with 1,2-diamino-4,5-dimethoxybenzene using a previously described method (35, 37) with the following modifications: samples were acidified with 100 mM acetic acid for storage at -80°C and transferred (on cardice) between collaborating groups before derivatization to minimize degradation of nucleotides to MG (38), the HPLC mobile phase was 20 mM ammonium formate, pH 3.4, with isocratic 30% methanol from 0 to 40 min, a linear gradient of 30–48% methanol from 40 to 60 min, 90% methanol from 60 to 70 min for washing of the column, and reequilibration with the initial mobile phase for 5 min, and the adducts and internal standard were detected by fluorescence (excitation wavelength 352 nm, emission wavelength 395 nm) with a scanning fluorescence detector (model 474; Waters Instruments Inc., Rochester, MN). For 3-DG, glyoxal and MG: the retention time of derivatized adducts was 8.5, 22.4, and 38.3 min (retention time of the internal standard was 53.3 min), the recoveries were 52, 70, and 59%, the limits of detection (analyte concentration equivalent to 2 SDs of the intercept on the analyte/internal standard peak area ratio) were 21, 11, and 14 pmol, and the interbatch coefficients of variation were 15, 11, and 10% ($n = 9$), respectively. For application of the α -oxoaldehyde assay using 1,2-diamino-4,5-dimethoxybenzene as a derivatizing agent for the assay of 3-DG, the 3-DG adduct 2-(2,3,4-trihydroxybutyl)-6,7-dimethoxyquinoxaline (TDQ) was prepared, purified, and characterized. 3-DG (72 mg, 0.4 mmol) and 1,2-diamino-4,5-dimethoxybenzene dihydrochloride (48 mg, 0.2 mmol) were dissolved in hydrochloric acid (1.5 M, 1.75 ml) and stirred under nitrogen at room temperature for 6 h. The product mixture was neutralized to pH 7.4 by the addition of 2 M potassium bicarbonate (~ 1.3 ml), filtered (0.2-mm pore size), and TDQ purified by preparative reversed-phase HPLC. The column was a 2.5×8 cm ODS cartridge with a 2.5×1 cm precolumn, the flow rate 9.9 ml/min, the sample loading 1 ml of neutralized crude product, and the mobile phase 20 mM acetic acid, 10% methanol (0–12 min) with a linear gradient of 10–50% methanol (12–32 min). The eluate absorbance was monitored at 352 nm. The TDQ-containing fraction, retention interval 4–16 min, was collected from three runs, pooled, and lyophilized to dryness. TDQ was characterized: melting point $94\text{--}95^{\circ}\text{C}$ (decomposed); ^1H NMR (50% vol/vol $\text{CD}_3\text{CN-D}_2\text{O}$) 8.15 (s, 1H, H-3), 7.23 (s, ^1H , H-8), 7.19 (s, 1H, H-5), 3.97 (s, 6H, 6,7-MeO), 3.78 (ddd, 1H, H-3', JH2',H3' = 7.7 Hz, JH3',H4'a = 9.9 Hz, JH3', H4'b = 3.0 Hz), 3.76 (dd, 1H, H-1'b; JH1'a,H1'b = 10.1 Hz, JH1'b, H2' = 7.1 Hz), 3.67 (m, 1H, H-2'; JH1'a,H2' = 6.4 Hz, JH1'b,H2' = 7.1 Hz, JH2',H3' = 7.7 Hz), 3.62 (dd, 1H, H-1'a; JH1'a,H1'b = 10.1 Hz, JH1'a, H2' = 6.4 Hz), 3.24 (dd, 1H, H-4'b; JH4'a,H4'b = 14.3 Hz, JH3', H4'b = 3.0 Hz), 3.00 (dd, 1H, H-4'a; JH4'a,H4'b = 14.3 Hz, JH3', H4'a = 9.9 Hz). ^{13}C -NMR (^1H decoupled, 50% vol/vol $\text{CD}_3\text{CN-D}_2\text{O}$) 153.6 (C-7), 153.5 (C-6), 152.9 (C-2), 144.3 (C-3), 139.3 (C-9), 138.1 (C-10), 106.6 (C-8), 106.2 (C-5), 63.5 (C-4'), 72.5 (C-3'), 75.4 (C-2'), 56.8 (C-6,7-MeO), and 39.3 (C-1'); fast atom bombardment mass spectrometry (glycerol matrix), $(m + 1)/z = 295$.

Measurement of intracellular D-lactate. Cytosolic fractions from 1.5×10^9 cells were deproteinized by adding perchloric acid (0.7 M). After centrifugation, the supernatant was adjusted to pH 6.0 with 5 N KOH followed by a second centrifugation. D-Lactate in the supernatant was measured using an HPLC method after conversion into 2-methylquinoxanol as described by Ohmori et al. (39). Briefly, to 0.5 ml of the supernatant, 300 μl of 0.1 M potassium phosphate, pH

7.7, and 50 μl of 52.5 mM hydrazine sulfate (Sigma Chemical Co.) were added. The mixture was incubated for 30 min at 37°C . 250 μl of 26 mM thioctamide, 50 μl of 62.5 U/ml of diaphorase (ICN Biomedicals, Inc., Irvine, CA), 50 μl of 25 mM NAD (Sigma Chemical Co.), and either 50 μl of 500 U/ml of D-LDH (Sigma Chemical Co.) or 50 μl of water were then added, and the incubations were continued for 2 h at 37°C . Then 238 μl of 35 mM *O*-phenylenediamine (Sigma Chemical Co.) and 0.3 ml of 1.5 N hydrochloric acid were added and allowed to react at 50°C for 1 h with shaking. The reaction mixture was adjusted to pH 3.0 with 2 M sodium phosphate and extracted with 2 ml of ethylacetate twice. The ethylacetate layer was evaporated and redissolved in 0.5 ml of the mobile phase (10 mM potassium phosphate, pH 2.9/acetonitrile [76:24]). HPLC was performed on a $5 \mu\text{m}$ C-18 column (Prodigy; Phenomenex Inc., Torrance, CA), 4.6×250 mm, at a 1 ml/min flow rate and detected with UV detector (Dynamax; Rainin Instruments Co., Woburn, MA) at 334 nm (excitation wavelength 341 nm). The value of 2-methylquinoxanol incubated without D-LDH was subtracted from the value with D-LDH.

Measurement of acetol. The assay was performed using a previously described method with slight modification (40). The same procedure was used for sample preparation as that used in the D-lactate assay. The acetol derivative formed with 2,4-dinitrophenylhydrazine was separated using a $5 \mu\text{m}$, C-18 column (Spherex; Phenomenex, Inc.), 250×4.6 mm, with a linear gradient elution with water and methanol (initial conditions 55% methanol, 1 ml/min, final conditions 100% methanol, 2 ml/min) and detected with a UV/visible detector (Dynamax; Rainin Instruments Co.) at 365 nm.

Results

High glucose (30 mM) does not affect glyoxalase-I activity in GM7373 cells. To evaluate the effect of high glucose on glyoxalase-I activity in GM7373 cells, cells were incubated in media containing either 5 or 30 mM glucose for 7 d. Then, cytosolic fractions were extracted and glyoxalase-I activity was determined. No significant difference in enzyme activity was found between cells exposed to 5 and 30 mM glucose (0.69 ± 0.01 vs. 0.66 ± 0.01 $\mu\text{mol}/\text{min}/\text{mg}$ protein, $n = 3$, $P = \text{NS}$).

A glyoxalase-I inhibitor, HCCG, enhances hyperglycemia-induced intracellular AGE formation in GM7373 cells. To evaluate the effect of glyoxalase-I inhibition on intracellular AGE formation in GM7373 cells, cells were incubated in either 5 or 30 mM glucose, or 30 mM glucose containing 40 μM of a glyoxalase-I inhibitor, HCCG, for 4 d. The media were changed every 12 h. Intracellular AGE formation in the cells exposed to 30 mM glucose was increased 5.4-fold compared to 5 mM (1.40 ± 0.08 vs. 0.26 ± 0.02 total absorbance units, $n = 3$, $P < 0.001$). This hyperglycemia-induced AGE formation was enhanced an additional 2.4-fold in the presence of the glyoxalase-I inhibitor (3.20 ± 0.03 vs. 1.40 ± 0.08 total absorbance units, $n = 3$, $P < 0.001$).

Stable expression of human glyoxalase-I in GM7373 cells increases glyoxalase-I activity. To evaluate the effect of glyoxalase-I on intracellular AGE formation, a GM7373 endothelial cell line stably expressing human glyoxalase-I activity was generated as described in Methods. The expression of human glyoxalase-I protein was demonstrated by Western blotting using a polyclonal antibody against human glyoxalase-I. As shown in Fig. 2 (lanes 3 and 4), a single band around 20 kD was detected, which corresponds to the molecular mass of the monomeric subunit of human glyoxalase-I (20,774 D) (26). To evaluate glyoxalase-I activity in transfected cells, glyoxalase-I activity of cytosolic fractions was determined. The enzyme activity was increased about 28-fold in glyoxalase-I-transfected




Figure 2. Western blot of human glyoxalase-I protein in GM7373 cells. Lanes 1 and 2 are duplicates of *neo*-transfected cells. Lanes 3 and 4 are duplicates of glyoxalase-I-transfected cells.

cells compared with *neo*-transfected cells (21.8 ± 0.1 vs. 0.76 ± 0.02 $\mu\text{mol}/\text{min}/\text{mg}$ protein, $n = 3$, $P < 0.001$).

Glyoxalase-I expression in GM7373 endothelial cells reduces hyperglycemia-induced intracellular AGE formation, but does not affect CML or CEL content. Both *neo* cells and glyoxalase-I-expressing cells were incubated in either 5 or 30 mM glucose, to evaluate the effect of glyoxalase-I on hyperglycemia-induced intracellular AGE formation. AGE concentration in the cells was measured by dot blotting using an mAb against AGE. After the cells were exposed to 5 and 30 mM glucose for 7 d, cytosolic fractions were used for the measurement. Intracellular AGE formation in *neo*-transfected cells exposed to 30 mM glucose was increased 13.6-fold compared with the cells exposed to 5 mM glucose (2.58 ± 0.15 vs. 0.19 ± 0.03 total absorbance units, $n = 3$, $P < 0.001$), whereas intracellular AGE in glyoxalase-I-transfected cells was not increased by 30 mM glucose (0.25 ± 0.03 vs. 0.21 ± 0.08 total absorbance units, $n = 3$, $P = \text{NS}$). Analysis of two epitopes recognized by the antibody 6D12, CML and CEL, showed no differences between *neo*- and glyoxalase-I-transfected cells (CML: *neo* cells, 0.0126 ± 0.0010 mmol/mol lysine; glyoxalase-I-transfected cells, 0.0201 ± 0.0047 mmol/mol lysine, $n = 6$, $P = \text{NS}$; CEL: *neo* cells, 0.0387 ± 0.0093 mmol/mol lysine; glyoxalase-I-transfected cells, 0.0286 ± 0.0056 mmol/mol lysine, $n = 6$, $P = \text{NS}$).

Glyoxal and 3-DG levels in endothelial cells are low and are not increased significantly by 30 mM glucose. Glyoxal has been identified as a key intermediate in the autoxidative modification of proteins by glucose (11). 3-DG also has been thought to be an important intermediate in AGE formation in vivo (41, 42). We evaluated both glyoxal and 3-DG levels in both *neo*- and glyoxalase-I-transfected cells incubated in either 5 or 30 mM glucose. In both cell types exposed to either glucose con-

centration, both glyoxal and 3-DG levels were below the statistical limit of detection (glyoxal; < 11 pmol/ 10^6 cells and 3-DG; < 21 pmol/ 10^6 cells) (Table I).

Hyperglycemia-induced increased MG content is normalized by increased enzymatic reduction in glyoxalase-I-expressing GM7373 endothelial cells. Although MG content in *neo* cells exposed to 30 mM glucose was increased by 181% compared with the cells exposed to 5 mM glucose (35.5 ± 5.8 vs. 19.6 ± 1.6 pmol/ 10^6 cells, $P < 0.02$), there was no significant difference in MG content between 30 and 5 mM glucose in glyoxalase-I-transfected cells (18.9 ± 3.2 vs. 18.4 ± 5.8 pmol/ 10^6 cells, $P = \text{NS}$). We next measured D-lactate to evaluate the minimal cumulative effect of high glyoxalase-I activity on MG metabolism in either 30 or 5 mM glucose for 7 d. D-lactate content in *neo* cells in 30 mM glucose was increased 2.1-fold compared with *neo* cells in 5 mM glucose (21.0 ± 1.3 vs. 10.0 ± 1.2 pmol/ 10^6 cells, $n = 3$, $P < 0.01$). In contrast, in glyoxalase-I-transfected cells, the hyperglycemia-induced D-lactate formation in 30 mM glucose was markedly enhanced. D-lactate content was increased 11.4-fold compared to 5 mM glucose (107.1 ± 8.9 vs. 9.4 ± 0 pmol/ 10^6 cells, $n = 3$, $P < 0.001$).

Acetol level in *neo*- and glyoxalase-I-transfected cells incubated in 30 mM glucose is not increased significantly. The enzyme aldose reductase catalyzes the conversion of MG to acetol (15). To evaluate the role of acetol in intracellular AGE production, we measured the level of acetol in cells incubated in either 5 or 30 mM glucose. The acetol levels in both *neo*- and glyoxalase-I-transfected cells in either glucose concentration were equally low and there was no significant difference between them (< 8.0 pmol/ 10^6 cells).

Glyoxalase-I expression in GM7373 endothelial cells reduces hyperglycemia-induced increases in macromolecular endocytosis. Both *neo* cells and glyoxalase-I-expressing cells were incubated in either 5 or 30 mM glucose to evaluate the effect of glyoxalase-I on hyperglycemia-induced increases in endocytosis. The cellular endocytosis of horseradish peroxidase in *neo* cells exposed to 30 mM glucose for 10 d was increased 2.2-fold compared with cells exposed to 5 mM glucose (5.12 ± 0.14 AU/ 10^6 cells vs. 2.138 ± 0.02 AU/ 10^6 cells, $n = 3$, $P < 0.001$), whereas the endocytosis in glyoxalase-I-transfected cells was not increased (2.27 ± 0.02 AU/ 10^6 cells vs. 2.29 ± 0.03 AU/ 10^6 cells, $n = 3$, $P = \text{NS}$).

Discussion

In this study we found that endogenous glyoxalase-I activity was identical in GM7373 endothelial cells exposed to either 5

Table I. Effect of Glyoxalase-I on Glyoxal, MG, D-lactate, Acetol, and 3-DG Content in the *neo*- and Glyoxalase-I-transfected Cells Exposed to Either 5 or 30 mM Glucose

Cells	Glucose	Glyoxal	3-DG	MG	D-lactate	Acetol
	mM	pmol/ 10^6 cells	pmol/ 10^6 cells	pmol/ 10^6 cells	pmol/ 10^6 cells	pmol/ 10^6 cells
<i>neo</i>	5	$< 11^{\parallel}$	$< 21^{\parallel}$	19.6 ± 1.6	10.0 ± 1.2	$< 8.0^{\parallel}$
	30	< 11	< 21	$35.5 \pm 5.8^*$	$21.0 \pm 1.3^{\ddagger}$	< 8.0
Glyoxalase-I	5	< 11	< 21	18.4 ± 5.8	9.4 ± 0	< 8.0
	30	< 11	< 21	18.9 ± 3.2	$107.1 \pm 8.9^{\S}$	< 8.0

* $P < 0.02$ vs. *neo* 5 mM, $^{\ddagger}P < 0.01$ vs. *neo* 5 mM, $^{\S}P < 0.001$ vs. *neo* 5 mM, $^{\parallel}$ below statistical limit of detection.

or 30 mM glucose. As demonstrated previously (10), intracellular AGE concentration was increased by 30 mM glucose, as was macromolecular endocytosis. This hyperglycemia-induced intracellular AGE formation was significantly increased when glyoxalase-I was partially inhibited by HCCG, providing indirect evidence that 30 mM glucose increased AGE formation by generating MG. To examine directly the role of MG in hyperglycemia-induced intracellular AGE formation, GM7373 endothelial cells were generated that stably expressed human glyoxalase-I with a 28-fold higher glyoxalase-I activity than *neo*-transfected cells. In *neo*-transfected cells, 30 mM glucose incubation increased MG and D-lactate concentration approximately twofold. In contrast, in glyoxalase-I-transfected cells, 30 mM glucose incubation did not increase MG concentration at all, while increasing the terminal product of the glyoxalase pathway, D-lactate, > 10-fold. Incubation of *neo* cells in 30 mM glucose did not cause any change in the levels of glyoxal, 3-DG, or acetol, however, the measured levels were below the statistical detection limits. Most strikingly, overexpression of glyoxalase-I completely prevented hyperglycemia-induced AGE formation, and also prevented hyperglycemia-induced macromolecular endocytosis. These results indicate that hyperglycemia increases AGEs in GM7373 endothelial cells primarily, if not exclusively, by increasing the concentration of AGE-forming MG, and that hyperglycemia-induced increases in macromolecular endocytosis are a consequence of MG accumulation.

Intracellular glycation and AGE formation have been associated with low catalytic efficiency of aldehyde reductase in the diabetic rat kidney (43) and decreased mitogenic activity of basic fibroblast growth factor (bFGF) in cultured endothelial cells (10). After incubation of endothelial cells in 30 mM glucose for 168 h, AGE-modified bFGF was increased by 6.1-fold and bFGF mitogenic activity was reduced by 70% (10). Our finding that endogenous glyoxalase-I activity is unaffected by these incubation conditions suggests that the lysyl residue in the active site of mammalian glyoxalase-I (44) is not susceptible to modification by glucose, most likely because of its microenvironment (45).

Since MG has been associated with cellular toxicity (14), preliminary experiments were performed to establish the optimum concentration of the glyoxalase-I inhibitor HCCG. This competitive inhibitor of glyoxalase-I mimics the enediol intermediate associated with the glyoxalase-I reaction (18). At a concentration of 80 μ M, GM7373 cells died after 2 d, while at 40 μ M HCCG, there was no cell death as assessed by trypan blue exclusion. Thus the observed increase in hyperglycemia-induced AGE formation reflects MG produced by a partial inhibition of glyoxalase-I. To ensure that the mAb 6D12 recognized MG-modified proteins, we demonstrated a concentration-dependent increase in the immunoreactivity of 6D12 against HSA minimally modified with highly purified MG in vitro, when either protein or MG concentration was the independent variable (46). To determine whether the mAb 6D12 was in fact detecting changes in intracellular CML, MG-derived CEL, or an unidentified MG-derived epitope, CML and CEL were quantitated using gas chromatography/mass spectrometry in both *neo*- and glyoxalase-I-transfected cells. Since analysis of both CML and CEL content showed no differences between *neo*- and glyoxalase-I-transfected cells, it is likely that the AGE formed by MG and recognized by 6D12 is a different MG protein epitope.

Our finding that incubation in 30 mM glucose increases concentrations of MG and its metabolite D-lactate in *neo*-transfected cells is consistent with the finding that MG concentration is increased three- to fivefold in the blood of diabetic patients (47). The lack of increase in MG concentration after incubation of cells overexpressing glyoxalase-I in high glucose and much greater increase in D-lactate are consistent with greater enzymatic conversion of MG to its metabolite, and suggest that glyoxalase-I activity is rate-limiting in hyperglycemia-induced increases in MG production. Intracellular concentrations of glyoxal and 3-DG were not detectable even after incubation in 30 mM glucose, suggesting that in these cells, glucose autoxidation and Amadori product decomposition did not occur to a significant degree. This conclusion is indirectly supported by the observation that overexpression of glyoxalase-I, which does not utilize 3-DG as a substrate, completely inhibited hyperglycemia-induced intracellular AGE formation. Elevated concentrations of 3-DG and its reduction product 3-deoxyfructose have been reported in blood from both animal and human diabetics (41, 42), however, suggesting that this intermediate may play a major role in extracellular AGE formation and/or in intracellular AGE formation in other cell types.

Acetol was also not detected even after incubation in 30 mM glucose, suggesting that conversion of MG to this alternate AGE precursor by aldose reductase (15) does not take place to any significant extent in these cells. Thus aldose reductase inhibitors are unlikely to increase intracellular AGE formation, and may even reduce MG formation by preventing the redox-induced inactivation of glyceraldehyde 3-phosphate dehydrogenase (5) and by preventing the hyperglycemia-induced depletion of the glutathione reductase cofactor NADPH (48).

The demonstration that hyperglycemia-induced intracellular AGE formation and increased macromolecular endocytosis in GM7373 endothelial cells result from increased MG production has important implications for the pathogenesis of diabetic vascular complications. Diabetes induces increased endothelial endocytosis in retinal capillaries in vivo, which may contribute to the capillary pathology that subsequently occurs (49).

Differences in the efficiency with which individual patients detoxify MG may explain individual differences in susceptibility to complications, while elucidation of the biochemical mechanisms by which hyperglycemia increases intracellular MG concentrations may lead to novel therapeutic strategies. Both of these possibilities deserve further exploration.

Acknowledgments

We would like to thank Dr. D.J. Creighton (Department of Chemistry and Biochemistry, University of Maryland, Baltimore, MD) for his generosity in providing us with the HCCG used in this study. We are grateful to Drs. Seikoh Horiuchi and Norie Araki (Department of Biochemistry, University of Kumamoto Medical School, Kumamoto, Japan) for providing us with mAb 6D12. We appreciate the kindness of Dr. Kenneth D. Tew (Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA) for providing us with the human glyoxalase-I cDNA and anti-human glyoxalase-I polyclonal antibody. We also appreciate the kindness of Dr. Milton Feather (Department of Chemistry, University of Missouri, Columbia, MO) for providing purified 3-DG.

This work was supported in part by National Institutes of Health grants DK-33861 (M. Brownlee) and DK19971 (S. Thorpe).

References

- Nathan, D. 1994. Relationship between metabolic control and long term complications of diabetes. In Joslin's Diabetes. C.R. Kahn and G. Weir, editors. Lea and Febiger, Philadelphia, PA. 620–631.
- Kuusisto, J., L. Mykkanen, K. Pyorala, and M. Laakso. 1994. NIDDM and its metabolic control predict heart disease in elderly subjects. *Diabetes*. 96:7.
- Kjensen-Urstad, K.J., P.G. Reichard, J.S. Rosfors, L. Lindblad, and M.T. Jensen-Urstad. 1996. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM. *Diabetes*. 45:1253–1258.
- Greene, D., S.A. Lattimer, and A.A.F. Sima. 1987. Sorbitol, phosphoinositides and sodium-potassium ATPase in the pathogenesis of diabetic complications. *N. Engl. J. Med.* 316:599–606.
- Williamson, J.R., K. Chang, M. Frangos, K.S. Hassan, Y. Ido, T. Kawamura, J.R. Nyengaard, M. van den Enden, C. Kilo, and R.G. Tilton. 1993. Hyperglycemic pseudohypoxia and diabetic complications. *Diabetes*. 42:801–813.
- King, G.L., T. Shiba, J. Oliver, T. Inoguchi, and S.E. Bursell. 1994. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. *Annu. Rev. Med.* 45:179–188.
- Graier, W.F., S. Simecek, W.R. Kurovets, and G.M. Kostner. 1996. High D-glucose-induced changes in endothelial Ca²⁺/EDRF signaling are due to generation of superoxide anion. *Diabetes*. 45:1386–1395.
- Vlassara, H., R. Bucala, and L. Striker. 1994. Pathogenic effects of AGEs: biochemical, biologic, and clinical implications for diabetes and aging. *Lab. Invest.* 70:138–151.
- Brownlee, M. 1995. Advanced protein glycosylation in diabetes and aging. *Annu. Rev. Med.* 46:223–234.
- Giardino, I., D. Edelstein, and M. Brownlee. 1994. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. *J. Clin. Invest.* 94:110–117.
- Wells-Knecht, K.J., D.V. Zyzak, J.E. Litchfield, S.R. Thorpe, and J.W. Baynes. 1995. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. *Biochemistry*. 34:3702–3709.
- Wells-Knecht, M.C., S.R. Thorpe, and J.W. Baynes. 1995. Pathways of formation of glycoxidative products during glycation of collagen. *Biochemistry*. 34:15134–15141.
- Thornalley, P.J. 1990. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. *Biochem. J.* 269:1–11.
- Thornalley, P.J. 1996. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification—a role in pathogenesis and antiproliferative chemotherapy. *Gen. Pharmacol.* 27:565–573.
- Vander Jag, D.L., B. Robinson, K.K. Taylor, and L.A. Hunsaker. 1992. Reduction of trioses by NADPH-dependent aldo-keto reductases: aldose reductase, methylglyoxal, and diabetic complications. *J. Biol. Chem.* 267:4364–4369.
- Stitt, A.W., U. Chakravarthy, D.B. Archer, and T.A. Gardiner. 1995. Increased endocytosis in retinal vascular endothelial cells grown in high glucose medium is modulated by inhibitors of nonenzymatic glycosylation. *Diabetologia*. 38:1271–1275.
- Presta, M., J.A. Maier, M. Rusnati, and G. Ragnotti. 1989. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. *J. Cell. Physiol.* 140:68–74.
- Murthy, N.S., T. Bakeris, M.J. Kavarana, D.S. Hamilton, and Y. Lan. 1994. S-(N-aryl-N-hydroxycarbonyl) glutathione derivatives are tight-binding inhibitors of glyoxalase I and slow substrates for glyoxalase II. *J. Med. Chem.* 37:2161–2166.
- Bischoff, J., and H.F. Lodish. 1987. Two asialoglycoprotein receptor polypeptides in human hepatoma cells. *J. Biol. Chem.* 262:11825–11832.
- Oray, B., and S.J. Norton. 1982. Glyoxalase I from mouse liver. *Methods Enzymol.* 90:542–546.
- Ikeda, K., T. Higashi, H. Sano, Y. Jinnouchi, M. Yoshida, T. Araki, S. Ueda, and S. Horiuchi. 1996. N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. *Biochemistry*. 35:8075–8083.
- Giardino, I., D. Edelstein, and M. Brownlee. 1996. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. *J. Clin. Invest.* 97:1422–1428.
- Westwood, M.E., A.C. McLellan, and P.J. Thornalley. 1994. Receptor-mediated endocytic uptake of methylglyoxal-modified serum albumin: competition with advanced glycation end product-modified serum albumin at the advanced glycation end product receptor. *J. Biol. Chem.* 269:32293–32298.
- Fu, M.X., J.R. Requena, A.J. Jenkins, T.J. Lyons, J.W. Baynes, and S.R. Thorpe. 1996. The advanced glycation end product, N-epsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. *J. Biol. Chem.* 271:9982–9986.
- Ahmed, M.U., D. Brinkmann Frye, T.P. Degenhardt, S.R. Thorpe, and J.W. Baynes. 1997. N-epsilon-(carboxymethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. *Biochem. J.* 324:565–570.
- Ranganathan, S., E.S. Walsh, A.K. Godwin, and K.D. Tew. 1993. Cloning and characterization of human colon glyoxalase-I. *J. Biol. Chem.* 268:5661–5667.
- Geller, A.I., and A. Feese. 1990. Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of *Escherichia coli* beta-galactosidase. *Proc. Natl. Acad. Sci. USA*. 87:1149–1153.
- Federoff, H.J., M.D. Geschwind, A.I. Geller, and J.A. Kessler. 1992. Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. *Proc. Natl. Acad. Sci. USA*. 89:1636–1640.
- Bergold, P.J., P. Casaccia-Bonnel, X.L. Zeng, and H.J. Federoff. 1993. Transsynaptic neuronal loss induced in hippocampal slice cultures by a herpes simplex virus vector expressing the GluR6 subunit of the kainate receptor. *Proc. Natl. Acad. Sci. USA*. 90:6165–6169.
- Starr, R.G., B. Lu, and H.J. Federoff. 1994. Functional characterization of the rat GAP-43 promoter. *Brain Res.* 638:211–220.
- Felgner, P.L., T.R. Gadek, M. Holm, R. Roman, H.W. Chan, M. Wenz, J.P. Northrop, G.M. Ringold, and M. Danielsen. 1987. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. *Proc. Natl. Acad. Sci. USA*. 84:7413–7417.
- Southern, P.J., and P. Berg. 1982. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. *J. Mol. Appl. Genet.* 1:327–341.
- McLellan, A.C., and P.J. Thornalley. 1992. Synthesis and chromatography of 1,2-diamino-4,5-dimethoxybenzene, 6,7-dimethoxy-2-methylquinoxaline, and 6,7-dimethoxy-2,3-dimethylquinoxaline for use in a liquid chromatographic fluorimetric assay of methylglyoxal. *Anal. Chim. Acta.* 263:137–142.
- Madson, M.A., and M.S. Feather. 1981. An improved preparation of 3-deoxy-D-erythro-hexos-2-ulose via bis (benzoylhydrazone) and some related constitutional studies. *Carbohydr. Res.* 94:183–191.
- McLellan, A.C., S.A. Phillips, and P.J. Thornalley. 1992. The assay of methylglyoxal in biological systems by derivatization with 1,2-diamino-4,5-dimethoxybenzene. *Anal. Biochem.* 206:17–23.
- Clelland, J.D., and P.J. Thornalley. 1991. S-2-hydroxyacylglutathione-derivatives: enzymatic preparation, purification, and characterisation. *J. Chem. Soc. Perkin Trans. I.* 3009–3015.
- Thornalley, P.J., A.C. McLellan, T.W.C. Lo, J. Benn, and P.H. Sonksen. 1991. Negative association of red blood cell-reduced glutathione with diabetic complications. *Clin. Sci.* 91:575–582.
- Chaplen, F.W.R., W.E. Fahl, and D.C. Cameron. 1996. Method for determination of free intracellular and extracellular methylglyoxal in animal cells grown in culture. *Anal. Biochem.* 238:171–178.
- Ohmori, S., and T. Iwamoto. 1988. Sensitive determination of D-lactic acid in biological samples by high-performance liquid chromatography. *J. Chromatogr.* 431:239–247.
- Casazza, J.P., and J.L. Fu. 1985. Measurement of acetol in serum. *Anal. Biochem.* 148:344–348.
- Yamada, H., S. Miyata, N. Igaki, H. Yatabe, Y. Miyauchi, T. Ohara, M. Sakai, H. Shoda, M. Oimomi, and M. Kasuga. 1994. Increase in 3-deoxyglucosone levels in diabetic rat plasma. Specific in vivo determination of intermediate in advanced Maillard reaction. *J. Biol. Chem.* 269:20275–20280.
- Wells-Knecht, K.J., T.J. Lyons, D.R. McCance, S.R. Thorpe, M.S. Feather, and J.W. Baynes. 1994. 3-Deoxyfructose concentrations are increased in human plasma and urine in diabetes. *Diabetes*. 43:1152–1156.
- Takahashi, M., Y.B. Lu, T. Myint, J. Fujii, Y. Wada, and N. Taniguchi. 1995. In vivo glycation of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of glycation sites. *Biochemistry*. 34:1433–1438.
- Aronsson, A.C., S. Sellin, G. Tibbelin, and B. Mannervik. 1981. Probing the active site of glyoxalase I from human erythrocytes by use of the strong reversible inhibitor S-p-bromobenzylglutathione and metal substitutions. *Biochem. J.* 197:67–75.
- Nacharaju, P., and A.S. Acharya. 1992. Amadori rearrangement potential of hemoglobin at its glycation sites is dependent on the three-dimensional structure of protein. *Biochemistry*. 31:12673–12679.
- Westwood, W.E., and P.J. Thornalley. 1995. Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. *J. Protein Chem.* 14:359–372.
- McLellan, A.C., P.J. Thornalley, J. Benn, and P.H. Sonksen. 1994. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. *Clin. Sci.* 87:21–29.
- Phillips, S.A., D. Mirrlees, and P.J. Thornalley. 1993. Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil. *Biochem. Pharmacol.* 46:805–811.
- Gardiner, T.A., A.W. Stitt, and D.B. Archer. 1995. Retinal vascular endothelial cell endocytosis increases in early diabetes. *Lab. Invest.* 72:439–444.